Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marc Scherlinger, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Scherlinger M, Schaeverbeke T. Correspondence on 'Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting'. Ann Rheum Dis. 2021 Mar 23. PMID: 33757969.
    Citations:    Fields:    
  2. Germain V, Scherlinger M, Barnetche T, Pichon C, Balageas A, Lequen L, Shipley E, Foret J, Dublanc S, Capuron L, Schaeverbeke T. Role of stress in the development of rheumatoid arthritis: a case-control study. Rheumatology (Oxford). 2021 02 01; 60(2):629-637. PMID: 32533144.
    Citations:    Fields:    
  3. Scherlinger M, Lutz J, Galli G, Richez C, Gottenberg JE, Sibilia J, Arnaud L, Blanco P, Schaeverbeke T, Chatelus E, Truchetet ME. Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments. Semin Arthritis Rheum. 2021 Feb; 51(1):36-42. PMID: 33360228.
    Citations:    Fields:    
  4. Injarabian L, Scherlinger M, Devin A, Ransac S, Lykkesfeldt J, Marteyn BS. Ascorbate maintains a low plasma oxygen level. Sci Rep. 2020 06 30; 10(1):10659. PMID: 32606354.
    Citations:    Fields:    Translation:HumansAnimalsCells
  5. Dos Santos Rocha A, Scherlinger M, Ostermann L, Mehler DMA, Nadiradze A, Schulze F, Feldmeyer L, de Koning M, Berbecar VT, Buijs R, Kijlstra JD, Jawaid A. Characteristics and opinions of MD-PhD students and graduates from different European countries: a study from the European MD-PhD Association. Swiss Med Wkly. 2020 04 06; 150:w20205. PMID: 32294222.
    Citations: 2     Fields:    
  6. Brilland B, Scherlinger M, Khoryati L, Goret J, Duffau P, Lazaro E, Charrier M, Guillotin V, Richez C, Blanco P. Platelets and IgE: Shaping the Innate Immune Response in Systemic Lupus Erythematosus. Clin Rev Allergy Immunol. 2020 Apr; 58(2):194-212. PMID: 31254159.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  7. Scherlinger M, Mertz P, Sagez F, Meyer A, Felten R, Chatelus E, Javier RM, Sordet C, Martin T, Korganow AS, Guffroy A, Poindron V, Richez C, Truchetet ME, Blanco P, Schaeverbeke T, Sibilia J, Devillers H, Arnaud L. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmun Rev. 2020 Jun; 19(6):102531. PMID: 32234406.
    Citations: 3     Fields:    Translation:Humans
  8. Ben Hassine I, Rein C, Comarmond C, Glanowski C, Saidenberg-Kermanac'h N, Meunier B, Schleinitz N, Chanson N, Sacré K, Scherlinger M, Richez C, Hirschi S, Groh M, Devilliers H, Bielefeld P, Saadoun D, Chapelon-Abric C, Arnaud L, Cacoub P. Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patients. Joint Bone Spine. 2019 Nov; 86(6):789-793. PMID: 31374357.
    Citations: 2     Fields:    Translation:Humans
  9. Scherlinger M, Carcaud C, Truchetet ME, Barnetche T, Duffau P, Couzi L, Seneschal J, Blanco P, Lazaro E, Richez C. Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study. Ann Rheum Dis. 2019 07; 78(7):1007-1010. PMID: 30610064.
    Citations: 3     Fields:    Translation:Humans
  10. Scherlinger M, Schaeverbeke T. 'To switch or not to switch': the missing piece in the puzzle of biosimilar literature? Ann Rheum Dis. 2020 04; 79(4):e36. PMID: 30610068.
    Citations:    Fields:    Translation:Humans
  11. Jacquemin C, Augusto JF, Scherlinger M, Gensous N, Forcade E, Douchet I, Levionnois E, Richez C, Lazaro E, Duffau P, Truchetet ME, Seneschal J, Couzi L, Pellegrin JL, Viallard JF, Schaeverbeke T, Pascual V, Contin-Bordes C, Blanco P. OX40L/OX40 axis impairs follicular and natural Treg function in human SLE. JCI Insight. 2018 12 20; 3(24). PMID: 30568041.
    Citations: 5     Fields:    Translation:HumansCells
  12. Scherlinger M, Pellegrin JL, Germain V, Lazaro E, Duffau P, Schaeverbeke T. [Biosimilars in France, to understand the stakes in order to use them well]. Rev Med Interne. 2019 Jan; 40(1):5-8. PMID: 30396704.
    Citations:    Fields:    Translation:Humans
  13. Germain V, Scherlinger M, Barnetche T, Schaeverbeke T. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect. Ann Rheum Dis. 2020 01; 79(1):e11. PMID: 30352888.
    Citations: 6     Fields:    Translation:Humans
  14. Grillon A, Scherlinger M, Boyer PH, De Martino S, Perdriger A, Blasquez A, Wipff J, Korganow AS, Bonnard C, Cantagrel A, Eyer D, Guérin F, Monteiro I, Woehl JM, Moreau P, Pennaforte JL, Lechevallier J, Bastides F, Colombey A, Imbert I, Maugars Y, Gicquel P, Cuchet F, Brax M, Sibilia J, Zilliox L, Barthel C, Arnaud L, Jaulhac B. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. Semin Arthritis Rheum. 2019 06; 48(6):1105-1112. PMID: 30344080.
    Citations: 4     Fields:    Translation:HumansCells
  15. Scherlinger M, Langlois E, Germain V, Schaeverbeke T. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Semin Arthritis Rheum. 2019 04; 48(5):927-932. PMID: 30093238.
    Citations: 15     Fields:    Translation:Humans
  16. Scherlinger M, Bienvenu TCM, Piffoux M, Séguin P. [MD-PhD trainings in France: overview and future directions, from the French MD/PharmD-PhD students association « AMPS »]. Med Sci (Paris). 2018 May; 34(5):464-472. PMID: 29900852.
    Citations: 1     Fields:    Translation:Humans
  17. Scherlinger M, Guillotin V, Truchetet ME, Contin-Bordes C, Sisirak V, Duffau P, Lazaro E, Richez C, Blanco P. Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets. Autoimmun Rev. 2018 Jun; 17(6):625-635. PMID: 29635077.
    Citations: 16     Fields:    Translation:HumansCells
  18. Scherlinger M, Schaeverbeke T. Additional response to the correspondence: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and Bennuci. Ann Rheum Dis. 2019 04; 78(4):e26. PMID: 29535122.
    Citations:    Fields:    Translation:Humans
  19. Scherlinger M, Schaeverbeke T. Response to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and Benucci. Ann Rheum Dis. 2019 04; 78(4):e24. PMID: 29374009.
    Citations:    Fields:    Translation:Humans
  20. Scherlinger M, Germain V, Labadie C, Barnetche T, Truchetet ME, Bannwarth B, Mehsen-Cetre N, Richez C, Schaeverbeke T. Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance. Joint Bone Spine. 2018 10; 85(5):561-567. PMID: 29154920.
    Citations: 13     Fields:    Translation:Humans
  21. Scherlinger M, Schaeverbeke T, Truchetet ME. Serum sickness-like disease after switching to biosimilar infliximab. Rheumatology (Oxford). 2017 Nov 01; 56(11):2032-2034. PMID: 28977481.
    Citations: 3     Fields:    Translation:Humans
  22. Scherlinger M, Sisirak V, Richez C, Lazaro E, Duffau P, Blanco P. New Insights on Platelets and Platelet-Derived Microparticles in Systemic Lupus Erythematosus. Curr Rheumatol Rep. 2017 Aug; 19(8):48. PMID: 28718063.
    Citations: 6     Fields:    Translation:HumansCells
  23. Scherlinger M, Alain S, Richez C. Monitoring of Epstein-Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritis. Joint Bone Spine. 2018 03; 85(2):259-260. PMID: 28363825.
    Citations: 2     Fields:    Translation:HumansCells
  24. Lazaro E, Scherlinger M, Truchetet ME, Chiche L, Schaeverbeke T, Blanco P, Richez C. Biotherapies in systemic lupus erythematosus: New targets. Joint Bone Spine. 2017 May; 84(3):267-274. PMID: 27663753.
    Citations: 3     Fields:    Translation:Humans
  25. Scherlinger M, Schaeverbeke T, Blanco P, Richez C. A unilateral erosive arthritis in a patient with systemic lupus erythematosus. Joint Bone Spine. 2017 03; 84(2):245-246. PMID: 27269652.
    Citations:    Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Scherlinger's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (124)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.